Articles

Cost effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression

ASCO 2016 – Lung Cancer

E1505: Adjuvant chemotherapy ± bevacizumab for early stage NSCLC—outcomes based on chemotherapy subsets

ASCO 2016 – Lung Cancer

Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC)

ASCO 2016 – Lung Cancer

Utilizing Chemotherapy to Treat Lung Cancer

ASCO 2016 – Lung Cancer

Benjamin P. Levy, MD, talks about the role chemotherapy currently plays in an arena where the cancer care team is emphasizing genomic profiling and targeted therapies to treat patients with lung cancer. Read More ›

Local consolidative therapy (LCT) to improve progression-free survival (PFS) in patients with oligometastatic non-small cell lung cancer (NSCLC) who receive induction systemic therapy (IST): Results of a multi-institutional phase II randomized study

ASCO 2016 – Lung Cancer

Nivolumab (nivo) vs docetaxel (doc) in patients (pts) with advanced NSCLC: CheckMate-017/057 2-y update and exploratory cytokine profile analyses

ASCO 2016 – Lung Cancer

Open-label, multicenter, randomized phase III trial of pemetrexed/carboplatin doublet vs pemetrexed singlet in chemotherapy-naïve elderly patients aged 70 or more with advanced non-squamous non–small-cell lung cancer and good performance status

ASCO 2016 – Lung Cancer

Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C

ASCO 2016 – Lung Cancer

Pooled analysis of venous thromboembolism (VTE) from four trials of necitumumab and chemotherapy for stage IV non-small cell lung cancer (NSCLC)

ASCO 2016 – Lung Cancer

Relationship between level of PD-L1 expression and outcomes in the KEYNOTE-010 study of pembrolizumab vs docetaxel for previously treated, PD-L1–positive NSCLC

ASCO 2016 – Lung Cancer

Page 117 of 143